Aberrant expression ofplays an oncogenic role in several types of cancer. However, the functions ofin lung adenocarcinoma (LUAD) remain unclear. Here, we investigated the regulatory function, clinical value, and prognostic significance ofin LUAD patients. The gene expression and DNA methylation data of LUAD tumor and paracancerous tissues were obtained from The Cancer Genome Atlas (TCGA) database. The association betweenexpression and clinicopathological variables was analyzed. The results showed thatwas highly expressed in LUAD tumor compared with paracancerous tissues, which was positively correlated with the race ( = 0.0448), tumor stage ( = 0.0191), and survival status ( < 0.001). Furthermore, the expression ofwas able to be regulated by the methylation inpromoter region, which was positively associated with the overall survival. Furthermore, we explored the related pathways through whichaffects the pathogenesis and prognosis of LUAD by gene set enrichment analysis, and found thatmight affect the clinical manifestations of LUAD by regulating the P53 signaling pathway. In the future, we would focus on exploring the molecular mechanism ofin the regulation of the occurrence and development of LUAD to provide a research basis for the screening of methylation markers related to the treatment and prognosis. LYPD3LYPD3LYPD3LYPD3LYPD3p p p LYPD3LYPD3LYPD3LYPD3LYPD3
